Technology
Health
Biotechnology

Bellicum Pharmaceuticals

$1.41
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-3.90%) Today
-$0.07 (-4.73%) As of 5:15 PM EDT after-hours

Why Robinhood?

You can buy or sell BLCM and other stocks, options, ETFs, and crypto commission-free!

About BLCM

Bellicum Pharmaceuticals, Inc. Common Stock, also called Bellicum Pharmaceuticals, is a clinical stage biopharmaceutical company, which focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Read More It uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

Employees
173
Headquarters
Houston, Texas
Founded
2004
Market Cap
69.25M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
519.89K
High Today
$1.55
Low Today
$1.47
Open Price
$1.54
Volume
370.14K
52 Week High
$7.27
52 Week Low
$1.47

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2014 IPO
US

BLCM Earnings

-$0.70
-$0.65
-$0.60
-$0.55
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.